切换至 "中华医学电子期刊资源库"

第五届中国出版政府奖音像电子网络出版物奖提名奖

中国科技核心期刊

中国科学引文数据库(CSCD)来源期刊

中华重症医学电子杂志 ›› 2024, Vol. 10 ›› Issue (01) : 85 -89. doi: 10.3877/cma.j.issn.2096-1537.2024.01.014

病例报告

TDM指导特重度烧伤脓毒症患者多黏菌素B的个体化治疗一例
刘霞1, 赵双平2,()   
  1. 1. 410008 长沙,中南大学湘雅医院重症医学科;413400 湖南桃江,湖南省益阳市桃江县人民医院重症医学科
    2. 410008 长沙,中南大学湘雅医院重症医学科
  • 收稿日期:2023-04-05 出版日期:2024-02-28
  • 通信作者: 赵双平

TDM guided the individualized treatment of polymyxin B in a patient with severe burn sepsis

Xia Liu1, Shuangping Zhao2,()   

  1. 1. Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha 410008, China;Department of Critical Care Medicine, Taojiang County People's Hospital, Taojiang 413400, China
    2. Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha 410008, China
  • Received:2023-04-05 Published:2024-02-28
  • Corresponding author: Shuangping Zhao
引用本文:

刘霞, 赵双平. TDM指导特重度烧伤脓毒症患者多黏菌素B的个体化治疗一例[J]. 中华重症医学电子杂志, 2024, 10(01): 85-89.

Xia Liu, Shuangping Zhao. TDM guided the individualized treatment of polymyxin B in a patient with severe burn sepsis[J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2024, 10(01): 85-89.

1例特重度烧伤患者,烧伤面积约85%(深Ⅱ~Ⅲ度),烧伤后创面急性大量渗出、持续19 d行连续性肾脏替代治疗(CRRT),继发创面、肺部、血流及消化道的泛耐药鲍曼不动杆菌感染,合并多器官功能衰竭,予以积极处理创面,仍有反复感染,多次启动以多黏菌素B为基础的联合治疗方案,并通过治疗药物监测(TDM)在治疗期间多次监测多黏菌素B的药物浓度,合理调整给药剂量,在患者行左小腿截肢术后,体质量发生变化,药物浓度较前偏高,后通过剂量调整,最终使患者感染得到有效控制。

One patient with extremely severe burn, with an area of about 85% (deep second to third degree), received continuous renal replacement therapy (CRRT) for 19 days. This was prompted by a sudden and significant release of fluid from the burn wound, followed by an infection caused by pan-drug resistant Acinetobacter baumannii. The infection affected various parts of the body, including the wound, lungs, bloodstream, and digestive tract, leading to multiple organ failure. Despite active treatment of the wound, the patient experienced recurring infections and required multiple rounds of combined treatment involving polymyxin B. Through therapeutic drug monitoring (TDM), the drug concentration of polymyxin B was monitored many times throughout treatment, allowing for appropriate dosage adjustment. After the amputation of the left leg, there was a change in body mass and an increase in drug concentration. Finally, through the adjustment of the dosage, the patient's infection was well controled.

图1 1例特重度烧伤患者每日出入水量
图2 1例特重度烧伤患者每日最高体温曲线
图3 1例特重度烧伤患者感染指标变化趋势图
图4 1例特重度烧伤患者抗生素使用情况
1
Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP) [J]. Pharmacotherapy, 2019, 39(1): 10-39.
2
罗高兴, 詹日兴, 袁志强, 等. 浅谈烧伤感染的分类与诊断命名 [J]. 中华烧伤与创面修复杂志, 2023, 39(4): 301-304.
3
张梓晨, 陈伟, 郑舒芩, 等. 498例成人特重度烧伤患者的临床资料分析 [J]. 昆明医科大学学报, 2022, 43(10): 90-97.
4
Oczkowski S, Alshamsi F, Belley-Cote E, et al. Surviving Sepsis Campaign Guidelines 2021: highlights for the practicing clinician [J]. Pol Arch Intern Med, 2022, 132(7-8): 16290.
5
中国医药教育协会感染疾病专业委员会, 中华医学会呼吸病学分会, 中华医学会重症医学分会, 等. 中国多黏菌素类抗菌药物临床合理应用多学科专家共识 [J]. 中华结核和呼吸杂志, 2021, 44(4): 292-310.
6
Munster AM, Xiao GX, Guo Y, et al. Control of endotoxemia in burn patients by use of polymyxin B [J]. J Burn Care Rehabil, 1989, 10(4): 327-330.
7
Lyons JM, Davis C, Rieman MT, et al. Prophylactic intravenous immune globulin and polymixin B decrease the incidence of septic episodes and hospital length of stay in severely burned children [J]. J Burn Care Res, 2006, 27(6): 813-818.
8
Kang JS, Lee MH. Overview of therapeutic drug monitoring [J]. Korean J Intern Med, 2009, 24(1): 1-10.
9
Martin-Loeches I. Therapeutic drug monitoring (TDM) in real-time: a need for the present future [J]. Expert Rev Anti Infect Ther, 2022, 20(10): 1245-1247.
10
Liu X, Huang C, Bergen PJ, et al. Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society [J]. Zhejiang Univ Sci B, 2023, 24(2): 130-142.
11
Malbrain MLNG, Van Regenmortel N, Saugel B, et al. Principles of fluid management and stewardship in septic shock: it is time to consider the four D's and the four phases of fluid therapy [J]. Ann Intensive Care, 2018, 8(1): 66.
12
Malbrain MLNG, Langer T, Annane D, et al. Intravenous fluid therapy in the perioperative and critical care setting: executive summary of the International Fluid Academy (IFA) [J]. Ann Intensive Care, 2020, 10(1): 64.
13
Jamal JA, Economou CJ, Lipman J, et al. Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation [J]. Curr Opin Crit Care, 2012, 18(5): 460-471.
14
Deng Y, Gu JY, Li X, et al. Does monitoring total and free polymyxin B1 plasma concentrations predict polymyxin B-induced nephrotoxicity? A retrospective study in critically ill patients [J]. Infect Dis Ther, 2022, 11(4): 1591-1608.
15
Sandri AM, Landersdorfer CB, Jovan J, et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis [J]. J Antimicrob Chemother, 2013, 68(3): 674-677.
16
张雨昇, 罗雪梅, 成晓亮, 等. CRRT对重症感染患者多黏菌素B血药浓度, 疗效及安全性的影响 [J]. 中国医院药学杂志, 2021, 41(22): 2342-2347.
17
孙仁华, 刘景全. 重症患者连续性肾脏替代治疗时抗生素剂量调整 [J]. 现代实用医学, 2016, 28(8): 981-984.
18
Sader HS, Rhomberg PR, Farrell DJ, et al. Differences in potency and categorical agreement between colistin and polymyxin B when testing 15, 377 clinical strains collected worldwide [J]. Diagn Microbiol Infect Dis, 2015, 83(4): 379-381.
[1] 韩媛媛, 热孜亚·萨贝提, 冒智捷, 穆福娜依·艾尔肯, 陆晨, 桑晓红, 阿尔曼·木拉提, 张丽. 组合式血液净化治疗对脓毒症患者血清炎症因子水平和临床预后的影响[J]. 中华危重症医学杂志(电子版), 2023, 16(04): 272-278.
[2] 张晓燕, 肖东琼, 高沪, 陈琳, 唐发娟, 李熙鸿. 转录因子12过表达对脓毒症相关性脑病大鼠大脑皮质的保护作用及其机制[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 540-549.
[3] 姚咏明. 如何精准评估烧伤脓毒症患者免疫状态[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 552-552.
[4] 张宪超, 张实. 基于转录组数据分析识别脓毒症肺炎免疫表型[J]. 中华肺部疾病杂志(电子版), 2023, 16(06): 761-765.
[5] 尚明煦, 魏丽娟, 是若春. 血清CRP、BNP、PCT与脓毒症并发ALI程度的相关性[J]. 中华肺部疾病杂志(电子版), 2023, 16(06): 766-769.
[6] 姜东, 冉龙艳, 雷传江, 徐静. 脓毒症的前世今生及序贯器官衰竭认知及理念[J]. 中华肺部疾病杂志(电子版), 2023, 16(05): 605-610.
[7] 许磊, 孙杰, 陈先志, 张家泉, 李旺勇, 冯其柱, 王琦. 血液净化治疗在高血脂性重症胰腺炎中的应用[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 464-468.
[8] 苗软昕, 乔晞. Toll样受体在脓毒症性急性肾损伤中的作用[J]. 中华肾病研究电子杂志, 2023, 12(04): 210-214.
[9] 石颖, 胡静, 刘佩本, 王婷婷, 左祥荣, 曹权. CAZ-AVI与多黏菌素B治疗重症CRKP肺炎患者的效果及安全性比较[J]. 中华重症医学电子杂志, 2024, 10(01): 16-24.
[10] 胡杰, 蔡国龙. 脓毒症合并低心功能指数患者PiCCO参数的聚类分析[J]. 中华重症医学电子杂志, 2024, 10(01): 25-30.
[11] 孙骎, 杨毅, 彭菲. Gasdermin蛋白家族在脓毒症细胞焦亡中的作用研究进展[J]. 中华重症医学电子杂志, 2023, 09(04): 379-384.
[12] 谭睿, 王晶, 於江泉, 郑瑞强. 脓毒症中高密度脂蛋白、载脂蛋白A-I和血清淀粉样蛋白A的作用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(06): 749-753.
[13] 蔡荇, 郑瑞强. 肝素结合蛋白在脓毒症中的应用及研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(04): 487-490.
[14] 高榕悦, 韩玉珍, 张晓珂, 游潘, 侯舒雅, 袁懿昕, 李文雄, 黄立锋. 钙卫蛋白对外科术后脓毒症患者的早期诊断价值[J]. 中华卫生应急电子杂志, 2023, 09(05): 263-269.
[15] 毛进, 张晨, 高娜, 夏泽燕, 吴宗盛. 脓毒性休克1 h集束化治疗在急诊中的实施情况及预后分析[J]. 中华卫生应急电子杂志, 2023, 09(04): 204-208.
阅读次数
全文


摘要